结肠癌中错配修复缺陷：一种预后还是预测生物标志物？ - Suppr

Suppr

超能文献

Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?

作者信息

Kerr David J, Midgley Rachel

出版信息

J Clin Oncol. 2010 Jul 10;28(20):3210-2. doi: 10.1200/JCO.2010.28.9322. Epub 2010 May 24.

DOI:10.1200/JCO.2010.28.9322

PMID:20498404

Abstract

摘要

相似文献

Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?

J Clin Oncol. 2010 Jul 10;28(20):3210-2. doi: 10.1200/JCO.2010.28.9322. Epub 2010 May 24.

Adjuvant 5-FU based chemotherapy for colon cancer: match or miss the mismatch?

Eur J Cancer. 2009 Feb;45(3):316-7. doi: 10.1016/j.ejca.2008.10.040. Epub 2008 Dec 25.

Predictive value of defective mismatch repair in adjuvant colon cancer.

J Clin Oncol. 2010 Dec 10;28(35):e746; author reply e747. doi: 10.1200/JCO.2010.31.8824. Epub 2010 Nov 1.

Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy.

J Clin Oncol. 1996 Oct;14(10):2887.

Effectiveness of adjuvant fluorouracil in elderly colon cancer patients: the internal and external validity of nonrandomized research design.

J Clin Oncol. 2003 May 1;21(9):1892; author reply 1893. doi: 10.1200/JCO.2003.99.238.

Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.

J Clin Oncol. 2004 May 1;22(9):1572-82. doi: 10.1200/JCO.2004.10.042.

[Adjuvant treatment for colon carcinoma. Results and perspectives].

Dtsch Med Wochenschr. 1998 May 22;123(21):674-80. doi: 10.1055/s-2007-1024037.

[Adjuvant therapy for colon cancer].

Dtsch Med Wochenschr. 2004 Oct 29;129(44):2366-71. doi: 10.1055/s-2004-835270.

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.

Eur J Cancer. 2009 Feb;45(3):365-73. doi: 10.1016/j.ejca.2008.07.016. Epub 2008 Aug 21.

Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.

Immunol Lett. 2005 Aug 15;100(1):88-93. doi: 10.1016/j.imlet.2005.06.011.

引用本文的文献

Personalizing adjuvant therapy for patients with colorectal cancer.

Nat Rev Clin Oncol. 2024 Jan;21(1):67-79. doi: 10.1038/s41571-023-00834-2. Epub 2023 Nov 24.

Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1.

Mol Clin Oncol. 2020 Nov;13(5):57. doi: 10.3892/mco.2020.2128. Epub 2020 Sep 1.

Microsatellite instability and manifestations of angiogenesis in stage IV of sporadic colorectal carcinoma.

Medicine (Baltimore). 2019 Jan;98(1):e13956. doi: 10.1097/MD.0000000000013956.

Prognostic Value of Mismatch Repair Genes for Patients With Colorectal Cancer: Meta-Analysis.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818808507. doi: 10.1177/1533033818808507.

Prognostic markers for colorectal cancer.

Oncotarget. 2018 Sep 4;9(69):33060-33061. doi: 10.18632/oncotarget.26012.

Chromatin organisation and cancer prognosis: a pan-cancer study.

Lancet Oncol. 2018 Mar;19(3):356-369. doi: 10.1016/S1470-2045(17)30899-9. Epub 2018 Feb 3.

Prognostic markers for colorectal cancer: estimating ploidy and stroma.

Ann Oncol. 2018 Mar 1;29(3):616-623. doi: 10.1093/annonc/mdx794.

Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.

Cancer Biol Ther. 2017 Dec 2;18(12):917-926. doi: 10.1080/15384047.2017.1385680. Epub 2017 Nov 20.

Mitotic crossover--an evolutionary rudiment which promotes carcinogenesis of colorectal carcinoma.

World J Gastroenterol. 2014 Sep 21;20(35):12522-5. doi: 10.3748/wjg.v20.i35.12522.

Prognostic and predictive significance of MSI in stages II/III colon cancer.

World J Gastroenterol. 2014 Jun 14;20(22):6809-14. doi: 10.3748/wjg.v20.i22.6809.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验